Clinical Trial Update: Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating the safety of adding aliskiren to ACE inhibitors or ARBs in patients with Type 2 diabetes and nephropathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy

Drugs mentioned

• Tekturna (aliskiren)

Snippet

Sponsor: Lerdsin General Hospital | Conditions: Type 2 Diabetes With Nephropathy | Phase 4 | Status: UNKNOWN